Product Pipeline

GNTbm focuses on the R&D of epigenetic regulation, tumor microenvironment regulation, epigenetic immune regulation, and immunoregulatory multi-kinase inhibitors. The first step is to develop new indications for Tucidinostat simultaneously with international pharmaceutical companies; the second is independent R&D of tumor microenvironment regulators (TMRs); the third, independently developed epigenetic immunoactivator (GNTbm-38) ; and the fourth is the independent development of immunoregulatory multi-kinase inhibitor drugs (GNTbm-TKI).


Product and Mechanisms

Introduction to the mechanisms of action of GNTbm products under development